Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
149 hedge funds and large institutions have $1.31B invested in Eagle Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 48 increasing their positions, 46 reducing their positions, and 16 closing their positions.
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
12% more call options, than puts
Call options by funds: $20.7M | Put options by funds: $18.4M
12% more capital invested
Capital invested by funds: $1.17B → $1.31B (+$136M)
9% more funds holding
Funds holding: 137 → 149 (+12)
4% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$12.6M |
| 2 |
CM
Castleark Management
Chicago,
Illinois
|
+$8.46M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.87M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.68M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
ProQuest Associates IV
Naples,
Florida
|
-$31.3M |
| 2 |
O
OrbiMed
New York
|
-$26.5M |
| 3 |
PC
PointState Capital
New York
|
-$21.3M |
| 4 |
JCI
Jet Capital Investors
New York
|
-$9.44M |
| 5 |
Morgan Stanley
New York
|
-$8.74M |
EGRX Hedge Fund Activity: Q4 2016 in Review
149 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2016, worth a combined $1.31B — up 12% from $1.17B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new EGRX positions and 16 closed out — a net gain of 15 holders — while 48 added to existing stakes and 46 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $12.6M. The largest seller was ProQuest Associates IV, cutting an estimated $31.3M.
- 149 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2016, up from 137 in Q3 2016.
- Funds reported $1.31B of Eagle Pharmaceuticals, Inc. stock for Q4 2016, up 12% quarter-over-quarter.
- 31 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2016 and 16 closed out, a net change of +15 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2016 was Victory Capital Management, an estimated $12.6M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2016 was ProQuest Associates IV, an estimated $31.3M sold.
Based on aggregated 13F filings for Q4 2016.